OA is characterized by progressive loss of articular cartilage, remodelling of the subchondral bone and osteophyte formation. 7, 8 Currently, increasing evidence has shown that osteoclast activity and bone remodelling increase in the early stage of OA, disturbing the equilibrium between bone formation and resorption that could eventually lead to a marked reduction in subchondral bone thickness. 9, 10 Moreover, the imbalance between bone formation and resorption leads to abnormal reconstruction of subchondral bone, which could promote the progression of OA. 11 This evidence provides a theoretical basis for targeting osteoclasts in the early stage of OA, which could be a useful intervention strategy for the treatment of OA.
Increasing evidence shows that reactive oxygen species (ROS) are one of the important destructive factors during OA development. 12 ROS perform various functions in cell energetic cycling, extracellular matrix metabolism and maintenance of chondrocyte homeostasis under physiological conditions. However, redundant production of ROS will break normal signalling and homeostasis. 13 Increased production of ROS is frequently found in OA, not only promoting osteoclastogenesis but also leading to matrix metalloproteases (MMPs) secretion and degradation of cartilage. [14] [15] [16] Moreover, ROS can induce dysregulation of mitochondria by depolarizing the mitochondrial membrane, which further results in increased ROS production 17, 18 and causes a vicious circle. Numerous studies have
shown that oxidative stress caused by ROS can induce apoptosis in chondrocytes. 19, 20 All of these findings highlight that ROS modulation may be a potential treatment for OA by inhibiting osteoclastogenesis and protecting chondrocytes.
Isorhamnetin (Iso), a 3′-methylated flavonol derived from herbal medicinal plants, has been shown to have a significant impact on many pathological processes. Iso was reported to protect against hypoxia/reoxygenation-induced injury by attenuating oxidative stress in cardiomyocytes. 21 Iso was also capable of inhibiting cancer cells migration, indicating that it could be a potential clinical chemotherapeutic approach for cancer. 22 Furthermore, Iso has been shown to be an effective compound that reduced IL-1β-induced expression of inflammatory mediators in human chondrocytes. 23 Despite these early reports indicating the translation potential in pre-clinical research, whether Iso could be used to treat OA by inhibiting osteoclasts and reducing ROS-induced chondrocyte apoptosis remains largely unexplored.
In the present study, we used receptor activator of nuclear factor-kappa B ligand (RANKL) to activate osteoclasts to mimic the pathological environment in the early stage of OA. We investigated the effects of Iso treatment on RANKL-induced osteoclast activation. Additionally, the underlying mechanisms regarding Iso-induced inhibition of osteoclastogenesis were investigated. 
| MATERIAL S AND ME THODS

| Cells, media and reagents
Primary bone marrow macrophages (BMMs) were cultured in α-minimum essential medium (α-MEM, HyClone, Logan, UT) containing 10% foetal bovine serum (Gibco, New York), 100 U/mL penicillin and 100 μg/mL streptomycin (Gibco, New York) at 37°C
in a humidified atmosphere with 5% CO 2 . Primary chondrocytes were cultured with Dulbecco's minimum essential medium (DMEM;
HyClone, Logan, UT) containing 10% foetal bovine serum, 100 U/ mL penicillin and 100 μg/mL streptomycin under the same conditions as BMMs. Iso was purchased from Herbpurify (Chengdu, China 
| BMMs isolation and culture
BMMs were obtained from the long bones of 6-week-old C57/BL6
mice. Briefly, after killing, the long bones, including femurs and tibias, were separated under aseptic conditions. All of the bone marrow was flushed from mouse femurs and tibias and then resuspended in complete α-MEM containing 30 ng/mL M-CSF. Cells were cultured in 75-cm 2 flasks and cultured in a 5% CO 2 incubator at 37°C. The media were changed every other day to remove nonadherent cells. At 80% confluence, the cells were washed with PBS three times and then trypsinized to harvest BMMs for the following experiments.
| Primary chondrocytes culture and immunofluorescence staining
Male C57BL/6J mice were killed and disinfected using 75% alcohol for 10 minutes. The head of the femur was exposed under aseptic conditions. All articular cartilage was isolated, collected and cut into 1 mm 3 pieces. The tissue was digested with 0.25% trypsin and 0.2% collagenase II for 30 minutes and 5 hours respectively. The cells were then filtered through a 70-μm cell strainer and washed three times with PBS. Next, the collected cells were seeded into culture dishes in DMEM at 37°C and 5% CO 2 . The culture medium was changed every other day. The expression of collagen II in chondrocytes after Iso treatment was analysed by immunofluorescence staining using collagen II antibody (Santa Cruz Biotechnology, CA).
| Cell viability assay
To evaluate the cytotoxic effects of Iso, cell viability was analysed using a cell counting kit-8 assay (CCK-8, Dojindo, Japan) following the manufacturer's protocol. In the in vitro assay, BMMs that were cultured with α-MEM containing 30 ng/mL M-CSF and chondro- With the assistance of mechanical agitation and sonication, the slides were washed with PBS to remove the cells. Resorption pits were imaged using scanning electron microscopy (SEM; FEI Instr., Hillsboro, OR).
| Quantitative real-time polymerase chain reaction (qRT-PCR) analysis
BMMs were seeded in a six-well plate at a density of Foster City, CA) according to a previous study. 26 The primers that were used are listed in Table S1 . The values were normalized to GAPDH mRNA expression levels and calculated using the 2 -ΔΔCt method.
| Western blotting
Western blotting analysis was performed according to a previously published protocol. 27 Total protein was extracted from BMMs and chondrocytes using radioimmunoprecipitation assay buffer (RIPA;
Millipore, MA) containing protease and phosphatase inhibitors. The protein concentrations were analysed using a BCA protein assay kit.
A total of 20 μg of protein was separated using 10% SDS-PAGE gel electrophoresis and then transferred to a polyvinylidene fluoride (PVDF) membrane. The membranes were blocked with 5% non-fat milk for 2 hours and incubated overnight at 4°C with primary antibodies. Furthermore, the membranes were incubated with secondary antibodies for 1 hour and washed in Tris-buffered saline with Tween (TBST). Fluorescent signals were detected using an Odyssey imaging system (Li-Cor, Lincoln, NE).
| Cell cycle analysis
Chondrocytes were treated with or without 25 μmol/L Iso for 24 hours. Cell cycle analysis was performed by propidium iodide (PI)
staining followed by analysis with a FACScan flow cytometer (BD, CA).
| Intracellular ROS detection
Levels of ROS in BMMs and chondrocytes were measured using DCFH-DA probe according to a previous study. 28 BMMs were cul- 
| Flow cytometry apoptosis analysis
| Measurement of mitochondrial membrane potential
The JC-1 fluorescent probe was purchased from Beyotime Biotech 
| Micro-CT scanning
At the end of 4 weeks after injection, the knee joints of the mice were harvested and fixed in 4% paraformaldehyde. Specimens were scanned using micro-CT (μCT 80; Scanco, Zurich, Switzerland) as described previously. 31 The micro-CT parameters were as follows:
voltage, 70 kV; electric current, 114 μA; and resolution of 10 μm per pixel. Three-dimensional structural parameters that were analysed included bone volume (BV), bone volume/total tissue volume (BV/ TV), trabecular number (Tb.N), trabecular thickness (Tb.Th) and trabecular separation (Tb.Sp).
| Histological observations
Samples were decalcified in 10% EDTA for 3 weeks and then embedded in paraffin. For microstructure observation, sagittal sections of the knee joint medial compartment were cut with a thickness of 4 μm and stained with haematoxylin and eosin (H&E), safranin O-fast green (S&F) and TRAP. Osteoarthritis Research Society International (OARSI) scores were calculated as previously described. 32 Moreover, TUNEL and MMP-3 (Santa, USA; dilution 1:100) immunohistochemical staining was accomplished. Total and positively stained chondrocytes in the entire articular cartilage were calculated.
| Statistical analysis
Each group contained three samples in vitro. All data were expressed as means ± standard deviations. One-way analysis of variance (ANOVA) was used for multifactorial comparisons in this study. 
| RE SULTS
| Iso inhibits RANKL-induced ROS production and osteoclastogenesis in vitro
The chemical structure of Iso is shown in Figure 1 . showed that osteoclast function was inhibited by Iso in vitro.
| Iso inhibits the expression of osteoclastogenesis-related genes and proteins in BMMs
Osteoclast differentiation is regulated by specifically related signalling pathways, which leads to the expression of particular genes. 33 The expression of osteoclastogenesis-related genes, including the nuclear factor of activated T-cells 1 (NFATc1), TRAP, c-FOS, DC-STAMP, cathepsin K and MMP-9, was analysed using quantitative real-time polymerase chain reaction (qRT-PCR). As shown in 
| Iso suppresses RANKL-induced activation of MAPK/NF-κB/AKT signalling pathways
Binding of RANKL to the receptor RANK could activate the MAPK pathway. 34 Three major MAPK signalling cascades, ERK, JNK and p38, have been shown to be crucial for activating osteoclast formation and function. As shown in Figure 3 , RANKL treatment clearly promoted phosphorylation of ERK, JNK and p38. However, phosphorylation of ERK, JNK and p38 considerably decreased after Iso treatment. RANKL-induced NF-κB activation is essential for initiating osteoclast differentiation. 35 As indicated in Figure 3 , western blotting analysis showed that RANKL treatment drastically caused degradation of IκBα while increasing phosphorylation of p65. However, Iso up-regulated IκBα expression and reduced phosphorylation of p65 in a dose-dependent manner. In addition to the MAPK/NF-κB pathway, the AKT-NFATc1 signalling axis has also been reported to be significant in osteoclast formation. 27 The results showed that RANKL treatment significantly increased phosphorylation of AKT in BMMs; however, the activation effects were substantially suppressed by Iso ( Figure 3 ). All of these results indicated that Iso could attenuate osteoclast formation by inhibiting MAPK/NF-κB/AKT pathways.
A schematic illustration shows the signalling pathways involved in osteoclast differentiation regulated by Iso in Figure 3 . Iso inhib- 
| The direct effects of Iso on chondrocytes
To investigate the direct effects of Iso on chondrocytes, a CCK-8 assay was first used to evaluate the cytotoxic effects of Iso. As shown in Figure S1A , the concentrations of Iso used to inhibit osteoclast formation (6.25, 12.5, 25 μmol/L) had minimal inhibitory effects on chondrocytes. Cell cycle analysis showed that Iso treatment did not noticeably affect the cell cycle of chondrocytes ( Figure   S1B ). Furthermore, Iso treatment had a minimal effect on the collagen II expression of chondrocytes ( Figure S1C ). All of these results indicated that Iso treatment did not directly affect chondrocytes.
Moreover, the viability of chondrocytes after various concentrations 
| Iso protects chondrocytes from ROSinduced apoptosis
The production of intracellular ROS was detected by DCFH-DA probe. We found that the number of ROS-positive cells was clearly increased in chondrocytes treated with H 2 O 2 for 24 hours. However, Iso could alleviate the production of ROS stimulated by H 2 O 2 in chondrocytes ( Figure 4 ). In addition, in the H 2 O 2 -treated group, the apoptosis rate was 16.26 ± 1.88%, which was reduced to 13.07 ± 2.82%, 
| Iso suppresses subchondral bone loss induced by ACLT in vivo
To investigate the effects of Iso on osteoclasts during the development of OA, we administered Iso intraperitoneally in ACLT-induced mice. As shown in Figure 6 , ACLT injury induced significant bone resorption in the subchondral bone as shown by the increased area of bone lesions in the μCT results. Nonetheless, the destruction was reduced by Iso treatment dose-dependently, showing increased integrity of the knee bone. Moreover, sagittal views of the medial compartment of subchondral bone showed that Iso decreased ACLT-induced bone resorption, indicating that osteolysis was diminished after Iso treatment ( Figure 6 ). Statistically, the tibial plateau BV was significantly less than that of the control group. Phosphorylated p65 translocates into the nucleus and binds to specific DNA sites to activate the expression of osteoclastogenesis-related genes. 43 Our results demonstrated that phosphorylation of p65 was markedly activated by RANKL stimulation in BMMs, whereas Iso suppressed NF-κB activation as indicated by the increased expression level of IκBα and decreased phosphorylation of p65. NFATc1 has been shown to be a key transcription factor that plays an important role in osteoclastogenesis. 44 Moreover, NFATc1
| Iso inhibits osteoclasts and protects chondrocytes in vivo
can activate varying osteoclastogenic genes associated with osteoclast differentiation and function, including c-FOS, TRAP, MMP-9, cathepsin K and DC-STAMP. 45 The AKT-NFATc1 signalling axis is important in osteoclast formation and it has been reported that inhibition of AKT activation could prevent RANKL-induced osteoclastogenesis. 46 In the present study, we found that Iso dramatically suppressed the phosphorylation of AKT activated by RANKL in BMMs. MAPK is in the serine-threonine protein kinase family that is involved in cell viability, differentiation, apoptosis, inflammation and innate immunity. 47 The most studied proteins of the MAPK pathway are ERK, JNK and p38 kinases, which can respond to extracellular stimuli including growth factors, heat shock proteins and pro-inflammatory cytokines. 48 Specific inhibitors of JNK, p38
and ERK can inhibit RANKL-stimulated osteoclast differentiation, indicating that MAPK is important for osteoclast activation and bone resorption. 49, 50 Our data showed that Iso clearly suppressed RANKL-induced phosphorylation of ERK in a dose-dependent man- 
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